Pfizer has announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. The single-dose vaccine offers protection against 20 clinically significant serotypes that cause the majority of invasive and non-invasive pneumococcal diseases.
According to the company, PCV20 provides timely and proactive protection for all adults, including those with chronic health conditions, and may eliminate the need for a second dose.
“With its broad coverage, PCV20 will help address the growing need for adult immunisation in India,” said Meenakshi Nevatia, Managing Director of Pfizer India.